1
|
Walden J, Brown L, Seiguer S, Munshaw K, Rausch J, Badawy S, McGann P, Winkler S, Gonzalez L, Creary S. Study protocol for ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness): Using small business partnerships to deliver a scalable and novel hydroxyurea adherence solution to youth with sickle cell disease. PLoS One 2024; 19:e0304644. [PMID: 38917111 PMCID: PMC11198815 DOI: 10.1371/journal.pone.0304644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2024] [Accepted: 05/13/2024] [Indexed: 06/27/2024] Open
Abstract
Sickle cell disease (SCD) is an inherited blood disorder that affects approximately 100,000 Americans, primarily from underrepresented racial minority populations, and results in costly, multi-organ complications. Hydroxyurea, the primary disease-modifying therapy for SCD, is effective at reducing most complications; however, adherence to hydroxyurea remains suboptimal and is the primary barrier to clinical effectiveness. Video directly observed therapy (VDOT) has shown promise as an adherence-promoting intervention for hydroxyurea, yet previous VDOT trials were limited by high attrition from gaps in technology access, use of unvalidated adherence measures, and healthcare system limitations of delivering VDOT to patients. As such, we fostered a small business partnership to compare VDOT for hydroxyurea to attention control to address previous shortcomings, promote equitable trial participation, and maximize scalability. VDOT will be administered by Scene Health (formerly emocha Health) and adherence monitoring will be performed using a novel electronic adherence monitor developed to meet the unique needs of the target population. Adolescent and young adult patients as well as caregivers of younger patients (<11 years of age) will be recruited. In addition to visit incentives, all participants will be offered a smartphone with a data plan to ensure all participants have equal opportunity to complete study activities. The primary objectives of this pilot, multi-center, randomized controlled trial (RCT) are to assess retention and sustained engagement and to explore needs and preferences for longer-term adherence monitoring and interventions. This RCT is registered with the National Institutes of Health (NCT06264700). Findings will inform a future efficacy RCT applying VDOT to hydroxyurea to address adherence gaps and improve outcomes within this vulnerable population.
Collapse
Affiliation(s)
- Joseph Walden
- Center for Child Health Equity and Outcomes Research, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States of America
| | - Lauren Brown
- emocha Mobile Health Inc. Doing Business as Scene and Scene Health, Baltimore, MD, United States of America
| | - Sebastian Seiguer
- emocha Mobile Health Inc. Doing Business as Scene and Scene Health, Baltimore, MD, United States of America
| | - Katie Munshaw
- emocha Mobile Health Inc. Doing Business as Scene and Scene Health, Baltimore, MD, United States of America
| | - Joseph Rausch
- Center for Biobehavioral Health, The Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States of America
- Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, OH, United States of America
| | - Sherif Badawy
- Division of Hematology, Oncology, and Stem Cell Transplant, Lurie Children’s Hospital of Chicago, Chicago, IL, United States of America
- Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America
| | - Patrick McGann
- Lifespan Comprehensive Sickle Cell Center, Providence, RI, United States of America
- The Warren Alpert Medical School of Brown University, Providence, RI, United States of America
| | - Savannah Winkler
- Division of Hematology, Oncology, and Stem Cell Transplant, Lurie Children’s Hospital of Chicago, Chicago, IL, United States of America
| | - Lisbel Gonzalez
- Lifespan Comprehensive Sickle Cell Center, Providence, RI, United States of America
| | - Susan Creary
- Center for Child Health Equity and Outcomes Research, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States of America
- Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, OH, United States of America
| |
Collapse
|
2
|
Forthun LF, Sajatovic M, Levin JB, DelBello MP, Appling D, Broadnax MD, Fuentes-Casiano E, Cooley R, Blixen CE, Modi AC. Modification of an Intervention to Improve Adherence in Adolescents and Young Adults With Bipolar Disorder. JAACAP OPEN 2023; 1:80-92. [PMID: 38143721 PMCID: PMC10745282 DOI: 10.1016/j.jaacop.2023.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/26/2023]
Abstract
Objective Managing bipolar disorder (BD) is particularly challenging for adolescents and young adults (AYAs) ages 16 to 21. Few interventions exist that address self-management in AYAs with BD. Thus, this study aimed to modify the customized adherence enhancement behavioral intervention for AYAs through an iterative, patient-centered process. Method The Obesity-Related Behavioral Intervention Trials (ORBIT) model was used for intervention development. In phase 1a, adherence barriers and facilitators were identified to refine intervention content. Phase 1b occurred following curriculum modification to ensure that the modified intervention was relevant and usable by the target population. Data were collected via focus groups and interviews with AYAs with BD, parents, and providers. Transcripts were analyzed using directed content analysis. Results Phase 1a included focus groups/interviews with AYAs (n = 10), parents (n = 4), and providers (n = 9) who described the difficulties and successes in managing BD symptoms, improving adherence, and transitioning care from caregivers. Phase 1b included an advisory board composed of 8 phase 1a participants who provided feedback on modified session activities, module delivery, and curriculum. Phase 1b involved usability testing with new participants (n = 8), revealing the need for modifiable language based on developmental level, more engaging visual images, and confirmation that topics were salient to AYAs with BD. Conclusion Though sample sizes were small and not representative of the population of AYAs with BD, the ORBIT methodology informed the adaptation of the customized adherence enhancement intervention to improve adherence in AYAs with BD. Important next steps are to conduct a pilot randomized clinical trial of customized adherence enhancement for AYAs.
Collapse
Affiliation(s)
- Larry F Forthun
- Dr. Forthun is with the University of Florida, Gainesville, Florida. Drs. Sajatovic, Levin, and Blixen, Mss. Broadnax and Fuentes-Casiano, and Mr. Appling are with Case Western Reserve University School of Medicine, Cleveland, Ohio, and University Hospitals of Cleveland Medical Center, Cleveland, Ohio. Dr. DelBello and Ms. Cooley are with the University of Cincinnati College of Medicine, Cincinnati, Ohio. Dr. Modi is with Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Martha Sajatovic
- Dr. Forthun is with the University of Florida, Gainesville, Florida. Drs. Sajatovic, Levin, and Blixen, Mss. Broadnax and Fuentes-Casiano, and Mr. Appling are with Case Western Reserve University School of Medicine, Cleveland, Ohio, and University Hospitals of Cleveland Medical Center, Cleveland, Ohio. Dr. DelBello and Ms. Cooley are with the University of Cincinnati College of Medicine, Cincinnati, Ohio. Dr. Modi is with Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Jennifer B Levin
- Dr. Forthun is with the University of Florida, Gainesville, Florida. Drs. Sajatovic, Levin, and Blixen, Mss. Broadnax and Fuentes-Casiano, and Mr. Appling are with Case Western Reserve University School of Medicine, Cleveland, Ohio, and University Hospitals of Cleveland Medical Center, Cleveland, Ohio. Dr. DelBello and Ms. Cooley are with the University of Cincinnati College of Medicine, Cincinnati, Ohio. Dr. Modi is with Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Melissa P DelBello
- Dr. Forthun is with the University of Florida, Gainesville, Florida. Drs. Sajatovic, Levin, and Blixen, Mss. Broadnax and Fuentes-Casiano, and Mr. Appling are with Case Western Reserve University School of Medicine, Cleveland, Ohio, and University Hospitals of Cleveland Medical Center, Cleveland, Ohio. Dr. DelBello and Ms. Cooley are with the University of Cincinnati College of Medicine, Cincinnati, Ohio. Dr. Modi is with Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Deionte Appling
- Dr. Forthun is with the University of Florida, Gainesville, Florida. Drs. Sajatovic, Levin, and Blixen, Mss. Broadnax and Fuentes-Casiano, and Mr. Appling are with Case Western Reserve University School of Medicine, Cleveland, Ohio, and University Hospitals of Cleveland Medical Center, Cleveland, Ohio. Dr. DelBello and Ms. Cooley are with the University of Cincinnati College of Medicine, Cincinnati, Ohio. Dr. Modi is with Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Michaela D Broadnax
- Dr. Forthun is with the University of Florida, Gainesville, Florida. Drs. Sajatovic, Levin, and Blixen, Mss. Broadnax and Fuentes-Casiano, and Mr. Appling are with Case Western Reserve University School of Medicine, Cleveland, Ohio, and University Hospitals of Cleveland Medical Center, Cleveland, Ohio. Dr. DelBello and Ms. Cooley are with the University of Cincinnati College of Medicine, Cincinnati, Ohio. Dr. Modi is with Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Edna Fuentes-Casiano
- Dr. Forthun is with the University of Florida, Gainesville, Florida. Drs. Sajatovic, Levin, and Blixen, Mss. Broadnax and Fuentes-Casiano, and Mr. Appling are with Case Western Reserve University School of Medicine, Cleveland, Ohio, and University Hospitals of Cleveland Medical Center, Cleveland, Ohio. Dr. DelBello and Ms. Cooley are with the University of Cincinnati College of Medicine, Cincinnati, Ohio. Dr. Modi is with Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Raechel Cooley
- Dr. Forthun is with the University of Florida, Gainesville, Florida. Drs. Sajatovic, Levin, and Blixen, Mss. Broadnax and Fuentes-Casiano, and Mr. Appling are with Case Western Reserve University School of Medicine, Cleveland, Ohio, and University Hospitals of Cleveland Medical Center, Cleveland, Ohio. Dr. DelBello and Ms. Cooley are with the University of Cincinnati College of Medicine, Cincinnati, Ohio. Dr. Modi is with Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Carol E Blixen
- Dr. Forthun is with the University of Florida, Gainesville, Florida. Drs. Sajatovic, Levin, and Blixen, Mss. Broadnax and Fuentes-Casiano, and Mr. Appling are with Case Western Reserve University School of Medicine, Cleveland, Ohio, and University Hospitals of Cleveland Medical Center, Cleveland, Ohio. Dr. DelBello and Ms. Cooley are with the University of Cincinnati College of Medicine, Cincinnati, Ohio. Dr. Modi is with Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Avani C Modi
- Dr. Forthun is with the University of Florida, Gainesville, Florida. Drs. Sajatovic, Levin, and Blixen, Mss. Broadnax and Fuentes-Casiano, and Mr. Appling are with Case Western Reserve University School of Medicine, Cleveland, Ohio, and University Hospitals of Cleveland Medical Center, Cleveland, Ohio. Dr. DelBello and Ms. Cooley are with the University of Cincinnati College of Medicine, Cincinnati, Ohio. Dr. Modi is with Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| |
Collapse
|
3
|
Reddy PS, Cai SW, Barrera L, King K, Badawy SM. Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents. Ann Med 2022; 54:683-693. [PMID: 35234095 PMCID: PMC8896206 DOI: 10.1080/07853890.2022.2044509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Sickle cell disease (SCD) results in severe complications, such as anaemia and pain episodes. Hydroxyurea (HU) is efficacious in SCD, yet adherence remains low. OBJECTIVE To assess the relationship of HU adherence to health care utilization and patients' characteristics. METHODS This is a 5-year retrospective chart review. Patients' demographics and medical history were collected from the electronic medical record (EMR). HU adherence was evaluated using foetal haemoglobin "HbF%", mean corpuscular volume "MCV", and absolute neutrophil count "ANC". Age groups included children (<12 years), adolescents (12-17 years), and young adults (≥18 years). RESULTS A total of 113 SCD patients on HU were included (median age 14 years, IQR 10-20; 50% female; 88% HbSS). Young adults had significantly higher HU adherence compared to adolescents and children, including higher median HbF% (24.2 vs. 12.4 vs. 8.6, p = .003), MCV (fl) (106.4 vs. 96.2 vs. 95.4, p = .01) and lower ANC (103/ml) (3.25 vs. 4.9 vs. 4.2, p = .01), respectively. Patients with chronic pain had lower HU adherence (HbF% 15.3 vs. 10.7, p = .04; ANC 3.6 vs. 6.3, p = .002; MCV 102.3 vs. 93.1, p = .1). Patients with higher HbF or MCV and lower ANC had significantly less frequent emergency room visits (rs=-0.26, p = .01; rs=-0.23, p = .01; rs=0.24, p = .01) and hospitalizations (rs=-0.27, p = .01; rs=-0.31, p = .01; rs=0.21, p = .02) as well as shorter length of stays (rs=-0.27, p = .0045; rs=-.34, p = 0.004; rs=0.23, p = .02), respectively. Similar trends in HU adherence and health care utilization were seen in subgroup analysis of only HbSS patients. There was no significant association of HU adherence to patients' sex, socio-economic status, distance from hospital, and HU duration. CONCLUSIONS Young adults with SCD had significantly higher HU adherence compared to children and adolescents. Patients with lower HU adherence and/or chronic pain had increased health care utilization. Future studies examining barriers to adherence and evaluating interventions to optimize HU adherence in SCD are warranted.KEY MESSAGESYoung adults with SCD had significantly higher HU adherence, as reflected in their laboratory markers, compared to children and adolescents.Patients with higher HU adherence and/or those without chronic pain had lower or less frequent health care utilization.No significant association of HU adherence to patients' sex, socio-economic status and distance from hospital.
Collapse
Affiliation(s)
- Paavani S Reddy
- Department of Medical Education, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Stephanie W Cai
- Department of Obstetrics & Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Leonardo Barrera
- Mary Ann & J. Milburn Smith Child Health Research, Outreach, and Advocacy Center, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA
| | - Kathryn King
- Division of Hematology, Oncology, and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA
| | - Sherif M Badawy
- Division of Hematology, Oncology, and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.,Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| |
Collapse
|